JP2001521382A5 - - Google Patents

Download PDF

Info

Publication number
JP2001521382A5
JP2001521382A5 JP1998542992A JP54299298A JP2001521382A5 JP 2001521382 A5 JP2001521382 A5 JP 2001521382A5 JP 1998542992 A JP1998542992 A JP 1998542992A JP 54299298 A JP54299298 A JP 54299298A JP 2001521382 A5 JP2001521382 A5 JP 2001521382A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP1998542992A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001521382A (ja
Filing date
Publication date
Priority claimed from US08/872,855 external-priority patent/US6121045A/en
Application filed filed Critical
Priority claimed from PCT/US1998/006775 external-priority patent/WO1998045434A1/en
Publication of JP2001521382A publication Critical patent/JP2001521382A/ja
Publication of JP2001521382A5 publication Critical patent/JP2001521382A5/ja
Pending legal-status Critical Current

Links

JP54299298A 1997-04-04 1998-04-06 新規なヒトデルタ3組成物ならびにそれらの治療および診断への使用方法 Pending JP2001521382A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US83263397A 1997-04-04 1997-04-04
US08/832,633 1997-04-04
US08/872,855 US6121045A (en) 1997-04-04 1997-06-11 Human Delta3 nucleic acid molecules
US08/872,855 1997-06-11
PCT/US1998/006775 WO1998045434A1 (en) 1997-04-04 1998-04-06 Novel human delta3 compositions and therapeutic and diagnostic uses therefor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009233349A Division JP2010004892A (ja) 1997-04-04 2009-10-07 新規なヒトデルタ3組成物ならびにそれらの治療および診断への使用方法

Publications (2)

Publication Number Publication Date
JP2001521382A JP2001521382A (ja) 2001-11-06
JP2001521382A5 true JP2001521382A5 (https=) 2005-11-24

Family

ID=27125549

Family Applications (1)

Application Number Title Priority Date Filing Date
JP54299298A Pending JP2001521382A (ja) 1997-04-04 1998-04-06 新規なヒトデルタ3組成物ならびにそれらの治療および診断への使用方法

Country Status (8)

Country Link
EP (1) EP0972041B2 (https=)
JP (1) JP2001521382A (https=)
AT (1) ATE342358T1 (https=)
AU (1) AU6952498A (https=)
CA (1) CA2285020A1 (https=)
DE (1) DE69836131T3 (https=)
ES (1) ES2275304T3 (https=)
WO (1) WO1998045434A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69638023D1 (de) 1995-06-28 2009-10-22 Univ Yale Nukleotid- und proteinsequenzen von delta-genen von vertebraten und darauf basierende methoden
US5780300A (en) * 1995-09-29 1998-07-14 Yale University Manipulation of non-terminally differentiated cells using the notch pathway
US20060122373A1 (en) 1997-04-04 2006-06-08 Millennium Pharmaceuticals, Inc. Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
US6664098B1 (en) * 1997-05-14 2003-12-16 Asahi Kasei Kabushiki Kaisha Differentiation inhibitory agent
EP1100899A2 (en) * 1998-07-27 2001-05-23 Amgen Inc. Delta-related polypeptides
AU6913100A (en) * 1999-08-19 2001-03-13 Chiron Corporation Notch receptor ligands and uses thereof
US6703221B1 (en) 1999-08-19 2004-03-09 Chiron Corporation Notch receptor ligands and uses thereof
GB9927328D0 (en) 1999-11-18 2000-01-12 Lorantis Ltd Immunotherapy
GB9927331D0 (en) 1999-11-18 2000-01-12 Fluorescience Ltd Assay for measuring enzyme activity in vivo
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
CA2457879A1 (en) * 2001-08-22 2003-03-06 Galapagos Genomics N.V. Modulators of bone homeostasis identified in a high-throughput screen
JP2003245084A (ja) 2001-12-20 2003-09-02 Morinaga Milk Ind Co Ltd 脳梁又は精子の形成不全の診断及び治療に有用な新規遺伝子、並びにその用途
US8048418B2 (en) 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
US7906116B2 (en) 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
CA2628221A1 (en) 2005-10-31 2007-05-10 Oncomed Pharmaceuticals, Inc. Anti-frizzled receptor antibodies for treating cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
NZ572177A (en) 2006-06-06 2012-02-24 Genentech Inc Anti-dll4 antibodies and methods using same
DK2066694T3 (en) 2006-09-29 2016-02-08 Oncomed Pharm Inc Compositions and Methods for Diagnosing and Treating Cancer
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
WO2008092002A2 (en) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
SG190568A1 (en) 2008-09-26 2013-06-28 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
CA2742969A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
HUE029661T2 (en) 2009-10-16 2017-03-28 Oncomed Pharm Inc A therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt拮抗劑及治療和篩選方法
DK2530091T3 (en) 2010-01-29 2018-05-28 Chugai Pharmaceutical Co Ltd ANTI-DLL3 ANTIBODY
CA2794674A1 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
LT3485903T (lt) 2011-09-23 2023-02-27 Mereo Biopharma 5, Inc. Vegf/ dll4 surišantys agentai ir jų panaudojimas
AU2013334790A1 (en) 2012-10-23 2015-04-30 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using Wnt pathway-binding agents
US9599620B2 (en) 2012-10-31 2017-03-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
ES2808153T3 (es) 2014-10-31 2021-02-25 Mereo Biopharma 5 Inc Terapia de combinación para tratamiento de enfermedad
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
JP7314146B2 (ja) 2017-12-28 2023-07-25 中外製薬株式会社 細胞傷害誘導治療剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL101728A (en) 1991-05-03 2007-08-19 Univ Yale Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them
US5786158A (en) 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
DE69638023D1 (de) 1995-06-28 2009-10-22 Univ Yale Nukleotid- und proteinsequenzen von delta-genen von vertebraten und darauf basierende methoden
US6337387B1 (en) * 1995-11-17 2002-01-08 Asahi Kasei Kabushiki Kaisha Differentiation-suppressive polypeptide

Similar Documents

Publication Publication Date Title
JP2000509912A5 (https=)
JP2000509635A5 (https=)
JP2000507042A5 (https=)
JP2000509942A5 (https=)
JP2000509637A5 (https=)
JP2000509587A5 (https=)
JP2000507369A5 (https=)
JP2000507433A5 (https=)
JP2000508866A5 (https=)
JP2000508022A5 (https=)
JP2001511733A5 (https=)
JP2000508841A5 (https=)
JP2001521382A5 (https=)
JP2000509804A5 (https=)
JP2000509853A5 (https=)
JP2000509755A5 (https=)
JP2000510969A5 (https=)
JP2002510303A5 (https=)
JP2000508836A5 (https=)
JP2000508102A5 (https=)
JP2001512521A5 (https=)
JP2000509520A5 (https=)
JP2000509818A5 (https=)
JP2000507434A5 (https=)
JP2000508880A5 (https=)